Gilead starts two late-stage studies to test drug for coronavirus

(Reuters) - Gilead Sciences Inc (GILD.O) said on Wednesday it has started two late-stage studies to test its drug in patients with severe and moderate cases of the illness caused by the coronavirus, sending its shares up 4% in extended trading.

GS-5734 structure.png

Beginning March, the studies will test the experimental antiviral drug, remdesivir, among nearly 1,000 patients at medical centers across Asian countries, as well as in other nations with high numbers of diagnosed cases, the company said.

Two dosing durations of remdesivir will be administered intravenously in the late-stage studies following the U.S. Food and Drug Administration’s rapid acceptance of remdesivir as a new investigational drug.

FEBRUARY 27, 2020

https://www.reuters.com/

0 items in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company